Blog

Support for Upfront Immunotherapy in Advanced Renal Cell Cancer – Medscape


Medscape

Support for Upfront Immunotherapy in Advanced Renal Cell Cancer
Medscape
Support for Upfront Immunotherapy in Advanced Renal Cell Cancer. Megan Brooks. February 05, 2018. In a phase 3 study of patients with previously untreated metastatic renal cell cancer (mRCC), use of the anti-PD-L1 immune checkpoint inhibitor

2018-02-05 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.